FDA Reviewers Flag Inconsistent Data for Rexulti in PTSD

(MedPage Today) — Whether brexpiprazole (Rexulti) is effective as adjunctive treatment for post-traumatic stress disorder (PTSD) will be debated at an FDA advisory committee meeting on Friday.
The atypical antipsychotic is under review as an…